2014: ESMO Study of HSP90 Inhibitor AT13387 alone and combo w/ Crizotinib in the treatment of NSCLC

Summary

Hsp90 is required for proper ALK function
AT13387 is a second generation Hsp90 inhibitor
AT13387 in ALK-driven pre-clinical models:
- Displays potent antitumor activity
- Delays the onset of resistance
In the clinic, AT133872
- Has a safety profile consistent with the class
- (diarrhea, mild transient visual changes)
  - PK & PD results support weekly dosing
  - Has antitumor activity (PR) at a dose of 220 mg/m2
    (D1,8,15 of 28 Day cycle)
Crizotinib (CZT) has demonstrated clinical activity in ALK-pos NSCLC3
AT13387-05 is a 3-part, Phase 1-2, randomized study